There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on AstraZeneca (AZN – Research Report) and Centessa Pharmaceuticals (CNTA – Research Report) with bullish sentiments.
AstraZeneca (AZN)
In a report released today, Etzer Darout from BMO Capital reiterated a Buy rating on AstraZeneca, with a price target of $80.00. The company’s shares closed last Tuesday at $68.41.
According to TipRanks.com, Darout is a 5-star analyst with an average return of
Currently, the analyst consensus on AstraZeneca is a Strong Buy with an average price target of $80.56, a 18.1% upside from current levels. In a report issued on March 27, Bank of America Securities also maintained a Buy rating on the stock.
See today’s best-performing stocks on TipRanks >>
Centessa Pharmaceuticals (CNTA)
BMO Capital analyst Kostas Biliouris maintained a Buy rating on Centessa Pharmaceuticals yesterday and set a price target of $15.00. The company’s shares closed last Tuesday at $11.31, close to its 52-week high of $12.45.
According to TipRanks.com, Biliouris is a 3-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Centessa Pharmaceuticals with a $13.33 average price target, representing a 23.4% upside. In a report issued on March 28, Leerink Partners also reiterated a Buy rating on the stock with a $14.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AZN:
- ZTS, EXAS, AZN: Which Biotech Stock Is the Better Buy?
- Nuvectis says NXP900 demonstrates robust activity in NSCLC
- AstraZeneca’s Enhertu Wins US Approval for Tumours
- ENHERTU approved for treatment of unresectable or metastatic HER2 positive
- AstraZeneca releases ADRIATIC Phase III trial results on IMFINZI
